These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1588355)

  • 1. Application of a stopping rule based on total treatment failures: the postoperative Crohn's disease trial.
    Steinhart AH; O'Rourke K; Wolff BG; McLeod RS
    J Clin Epidemiol; 1992 May; 45(5):495-504. PubMed ID: 1588355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease.
    McLeod RS; Wolff BG; Steinhart AH; Carryer PW; O'Rourke K; Andrews DF; Blair JE; Cangemi JR; Cohen Z; Cullen JB
    Gastroenterology; 1995 Aug; 109(2):404-13. PubMed ID: 7615189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
    Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
    Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group.
    Brignola C; Cottone M; Pera A; Ardizzone S; Scribano ML; De Franchis R; D'Arienzo A; D'Albasio G; Pennestri D
    Gastroenterology; 1995 Feb; 108(2):345-9. PubMed ID: 7835575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance treatment for Crohn's disease: has the time arrived?
    Goldstein F
    Am J Gastroenterol; 1992 May; 87(5):551-6. PubMed ID: 1350706
    [No Abstract]   [Full Text] [Related]  

  • 9. Postoperative recurrence of Crohn's disease: pathogenesis and prevention.
    D'Haens GR; Rutgeerts PJ
    Acta Gastroenterol Belg; 1994; 57(5-6):311-3. PubMed ID: 7709700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease.
    Mahida YR; Jewell DP
    Digestion; 1990; 45(2):88-92. PubMed ID: 2190851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
    Lochs H; Mayer M; Fleig WE; Mortensen PB; Bauer P; Genser D; Petritsch W; Raithel M; Hoffmann R; Gross V; Plauth M; Staun M; Nesje LB
    Gastroenterology; 2000 Feb; 118(2):264-73. PubMed ID: 10648454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
    Small RE; Schraa CC
    Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
    Arber N; Odes HS; Fireman Z; Lavie A; Broide E; Bujanover Y; Becker S; Pomerantz I; Moshkowitz M; Patz J
    J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
    Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
    Hanauer SB; Korelitz BI; Rutgeerts P; Peppercorn MA; Thisted RA; Cohen RD; Present DH
    Gastroenterology; 2004 Sep; 127(3):723-9. PubMed ID: 15362027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for prevention of post-operative recurrence of Crohn's disease.
    Doherty G; Bennett G; Patil S; Cheifetz A; Moss AC
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006873. PubMed ID: 19821389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
    Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
    J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
    Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
    Singleton JW; Hanauer S; Robinson M
    Dig Dis Sci; 1995 May; 40(5):931-5. PubMed ID: 7729281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
    Feagan BG; McDonald JW; Rochon J; Laupacis A; Fedorak RN; Kinnear D; Saibil F; Groll A; Archambault A; Gillies R
    N Engl J Med; 1994 Jun; 330(26):1846-51. PubMed ID: 8196727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.